Key Points
- Eric Lefkofsky sold 166,250 Tempus AI shares on Dec. 18 at an average of $63.99 for about $10.64M, trimming his stake by 1.82% to 8,974,783 shares valued at roughly $574.3M.
- Tempus beat estimates in its most recent quarter with EPS of ($0.11) and revenue of $334.2M (up 84.7% YoY), but the company remains unprofitable with a negative net margin and negative return on equity.
- Analysts are mixed—MarketBeat shows a consensus "Hold" rating with an average price target of $84—and the stock is highly volatile (52-week range $31.36–$104.32, beta ~5.0).
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 166,250 shares of the firm's stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $63.99, for a total value of $10,638,337.50. Following the completion of the transaction, the chief executive officer directly owned 8,974,783 shares in the company, valued at $574,296,364.17. The trade was a 1.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Tempus AI Price Performance
NASDAQ TEM opened at $65.92 on Tuesday. The company has a 50-day moving average price of $77.26 and a 200-day moving average price of $73.86. Tempus AI, Inc. has a 52 week low of $31.36 and a 52 week high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $11.73 billion, a P/E ratio of -55.39 and a beta of 5.00.
Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05. The company had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The firm's revenue was up 84.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.46) earnings per share. Equities research analysts anticipate that Tempus AI, Inc. will post -6.15 earnings per share for the current year.
Hedge Funds Weigh In On Tempus AI
Large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company's stock worth $762,032,000 after acquiring an additional 1,706,837 shares during the period. Voloridge Investment Management LLC lifted its holdings in Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company's stock worth $129,708,000 after purchasing an additional 1,039,176 shares in the last quarter. Franklin Resources Inc. boosted its stake in Tempus AI by 0.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company's stock worth $117,523,000 after purchasing an additional 5,375 shares during the period. BNP Paribas Financial Markets boosted its stake in Tempus AI by 312.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company's stock worth $102,869,000 after purchasing an additional 965,730 shares during the period. Finally, AQR Capital Management LLC grew its holdings in Tempus AI by 6.4% during the 3rd quarter. AQR Capital Management LLC now owns 904,872 shares of the company's stock valued at $73,032,000 after buying an additional 54,692 shares in the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. TD Cowen lowered Tempus AI from a "buy" rating to a "hold" rating and set a $88.00 price objective for the company. in a research note on Tuesday, October 21st. Needham & Company LLC boosted their price target on Tempus AI from $70.00 to $100.00 and gave the company a "buy" rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. decreased their price objective on Tempus AI from $85.00 to $80.00 and set a "neutral" rating on the stock in a research note on Monday, December 15th. BTIG Research lifted their price objective on Tempus AI from $96.00 to $105.00 and gave the company a "buy" rating in a research report on Tuesday, November 25th. Finally, Canaccord Genuity Group cut their price objective on Tempus AI from $95.00 to $80.00 and set a "buy" rating for the company in a research note on Monday. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tempus AI has a consensus rating of "Hold" and an average price target of $84.00.
View Our Latest Report on Tempus AI
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
